Adaptimmune Therapeutics plc (ADAP) News
Filter ADAP News Items
ADAP News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ADAP News Highlights
- For ADAP, its 30 day story count is now at 7.
- Over the past 29 days, the trend for ADAP's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about ADAP are BEAT, AGIO and AIM.
Latest ADAP News From Around the Web
Below are the latest news stories about Adaptimmune Therapeutics PLC that investors may wish to consider to help them evaluate ADAP as an investment opportunity.
Clovis (CLVS) Q4 Loss Narrower than Expected, Revenues LagClovis (CLVS) reports narrower-than-expected loss for fourth-quarter 2021. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts. |
Agios (AGIO) Gets FDA Nod for Rare Anemia Drug MitapivatAgios Pharmaceuticals' (AGIO) Pyrukynd (mitapivat) is the first disease-modifying therapy approved to treat PK deficiency, a rare, debilitating, blood disorder. |
Repligen (RGEN) Q4 Earnings and Revenues Surpass EstimatesRepligen's (RGEN) fourth-quarter earnings and revenues beat estimates. It expects to achieve revenue growth in the range of 19-24% in 2022. |
CRISPR Therapeutics (CRSP) Q4 Earnings Miss, Revenues Up Y/YCRISPR Therapeutics (CRSP) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates. |
Zoetis' (ZTS) Q4 Earnings and Revenues Surpass EstimatesZoetis' (ZTS) earnings and revenues beat estimates for the fourth quarter of 2021. |
Adaptimmune Therapeutics (NASDAQ:ADAP) shareholders have endured a 48% loss from investing in the stock a year agoIt's easy to match the overall market return by buying an index fund. Active investors aim to buy stocks that vastly... |
Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial OfficerPHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Cintia Piccina as Chief Commercial Officer effective January 31, 2022. “I am delighted to welcome Cintia to our leadership team. She brings extensive commercial experience, including in cell and gene therapy, that will be key as we prepare to submit our first BLA for afami-cel this year, and buil |
2 Cancer Stocks With Absurdly Low ValuationsThe potential for four or more interest rate hikes by the Federal Reserve over the course of 2022 has been weighing heavily on growth stocks of late. Investors are clearly pivoting toward safe havens like value and dividend stocks ahead of this perceived eventuality. Shares of the cancer specialists Adaptimmune Therapeutics (NASDAQ: ADAP) and Clovis Oncology (NASDAQ: CLVS) are both trading at absurdly low valuations following their steep downturns over the past several weeks. |
4 Biotechs That Could Be Potential Takeover Targets in 2022We discuss a few companies like BioMarin (BMRN), Adaptimmune (ADAP), CRISPR Therapeutics (CRSP), and Alnylam Pharmaceuticals (ALNY) with solid product portfolios, deep pipelines which make them attractive candidates for a potential takeover in 2022. |
Brokerages Anticipate Adaptimmune Therapeutics plc (NASDAQ:ADAP) Will Announce Earnings of $0.23 Per ShareWall Street analysts expect that Adaptimmune Therapeutics plc (NASDAQ:ADAP) will report earnings per share of $0.23 for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Adaptimmune Therapeutics’ earnings. The highest EPS estimate is $0.71 and the lowest is ($0.26). Adaptimmune Therapeutics posted earnings of ($0.24) per share in […] |